Market Overview

Celgene Says ABRAXANE Demonstrates Statistically Significant Improvement

Related CELG
Biotech Enters Reporting Season With Large Caps Central To Sector Performance
UPDATE: Morgan Stanley Reiterates On Celgene As EU Patents Risk May Be Underappreciated
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE^® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.

Posted-In: News FDA

 

Most Popular

Related Articles (CELG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free